实用临床医药杂志
實用臨床醫藥雜誌
실용림상의약잡지
JOURNAL OF JIANGSU CLINICAL MEDICINE
2014年
17期
44-46,51
,共4页
沙利度胺%化疗%非小细胞肺癌%血管内皮生长因子
沙利度胺%化療%非小細胞肺癌%血管內皮生長因子
사리도알%화료%비소세포폐암%혈관내피생장인자
thalidomide%chemotherapy%non-small cell lung cancer%vascular endothelial growth factor
目的：观察沙利度胺联合化疗方案治疗晚期非小细胞肺癌（NSCLC）的疗效，及其对血清血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）和肿瘤坏死因子（TNF-α）水平的影响。方法选取晚期NSCLC患者87例，随机分为观察组45例，对照组42例，对照组给予NP方案化疗，观察组在此基础上联合沙利度胺治疗，观察2组患者的临床疗效及血清VEGF、bFGF及TNF-α指标水平的变化。结果观察组临床受益率（CBR）显著高于对照组（P＜0．01）。治疗后2组患者血清VEGF水平均显著下降（P＜0．05），观察组血清bFGF水平显著下降（P＜0．05），对照组血清bFGF水平与治疗前无显著差异（P＞0．05）。2组患者治疗后血清TNF-α水平显著低于治疗前（P＜0．05或P＜0．01），且观察组显著低于对照组（P＜0．05）。结论沙利度胺联合化疗治疗晚期NSCLC具有一定的优势，能降低血清VEGF、bFGF及TNF-α指标水平。
目的：觀察沙利度胺聯閤化療方案治療晚期非小細胞肺癌（NSCLC）的療效，及其對血清血管內皮生長因子（VEGF）、堿性成纖維細胞生長因子（bFGF）和腫瘤壞死因子（TNF-α）水平的影響。方法選取晚期NSCLC患者87例，隨機分為觀察組45例，對照組42例，對照組給予NP方案化療，觀察組在此基礎上聯閤沙利度胺治療，觀察2組患者的臨床療效及血清VEGF、bFGF及TNF-α指標水平的變化。結果觀察組臨床受益率（CBR）顯著高于對照組（P＜0．01）。治療後2組患者血清VEGF水平均顯著下降（P＜0．05），觀察組血清bFGF水平顯著下降（P＜0．05），對照組血清bFGF水平與治療前無顯著差異（P＞0．05）。2組患者治療後血清TNF-α水平顯著低于治療前（P＜0．05或P＜0．01），且觀察組顯著低于對照組（P＜0．05）。結論沙利度胺聯閤化療治療晚期NSCLC具有一定的優勢，能降低血清VEGF、bFGF及TNF-α指標水平。
목적：관찰사리도알연합화료방안치료만기비소세포폐암（NSCLC）적료효，급기대혈청혈관내피생장인자（VEGF）、감성성섬유세포생장인자（bFGF）화종류배사인자（TNF-α）수평적영향。방법선취만기NSCLC환자87례，수궤분위관찰조45례，대조조42례，대조조급여NP방안화료，관찰조재차기출상연합사리도알치료，관찰2조환자적림상료효급혈청VEGF、bFGF급TNF-α지표수평적변화。결과관찰조림상수익솔（CBR）현저고우대조조（P＜0．01）。치료후2조환자혈청VEGF수평균현저하강（P＜0．05），관찰조혈청bFGF수평현저하강（P＜0．05），대조조혈청bFGF수평여치료전무현저차이（P＞0．05）。2조환자치료후혈청TNF-α수평현저저우치료전（P＜0．05혹P＜0．01），차관찰조현저저우대조조（P＜0．05）。결론사리도알연합화료치료만기NSCLC구유일정적우세，능강저혈청VEGF、bFGF급TNF-α지표수평。
Objective To observe the efficacy of thalidomide combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)and its influence on vascular endothe-lial growth factor (VEGF),basic fibroblast growth factor (bFGF)and tumor necrosis factor-α(TNF-α).Methods A total of 87 patients with advanced NSCLC were enrolled and randomly divided into observational group (45 cases)and control group (42 cases).Patients in control group received NP regimen while patients in observational group received thalidomide +NP regimen.The clinical effica-cy and the changes of the levels of VEGF,bFGF and TNF-αwere observed.Results Clinical benefit rate (CBR)of observational group was significantly higher than control group (P<0.01).Compared with treatment before,the levels of VEGF in 2 groups decreased significantly (P<0.05)and the lev-els of bFGF in observational group reduced obviously (P<0.05 )but there was no significant differ-ence between treatment before and after treatment (P>0.05).The level of TNF-αafter treatment in 2 groups was obviously lower than treatment before (P<0.05,or P<0.01 )and observational group was significantly lower than control group (P <0.05 ).Conclusion Thalidomide combined with chemotherapy can reduce the level of VEGF,bFGF and TNF-αin the treatment of advanced NSCLC.
